Informace o publikaci

Remarkable prognostic value and contribution in staging of F-18-FDG-positron emission tomography in follicular lymphoma

Autoři

KRÁL Zdeněk JANÍKOVÁ Andrea BOLČÁK Karol MAYER Jiří

Rok publikování 2008
Druh Článek ve sborníku
Konference Annals of Oncology 19; 2008 Suppl 4
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Klíčová slova FDG-PET, follicular lymphoma, prognosis
Popis Introduction: F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool for the imaging of aggressive NonHodgkin lymphomas and Hodgkin lymphoma. In contrast, there is relatively little data on FDG-PET in follicular lymphoma (FL) in spite of its high FDG uptake. Methods: A retrospective analysis of 127 FDG-PET scans was performed among 100 patients with FL (93% grade I or II). FDG-PET was obtained at initial staging (n= 56) and results were compared with conventional staging. Post-treatment scans (n=71, in 87% patients treated by conventional therapy) were compared with clinical follow-up. Results: FDG-PET compared with CT and clinical examination showed more foci of involvement in 30/56 (55%) FL patients, less in 7/56, the same extension in 15/56 and 4 patients revealed discordant founds on PET or CT only (p<0,001). FDG-PET upstaged essentially FL in 15 patients (from stage 0-2 to 3-4). Including results of trephine biopsy the stage was substantially changed in 13/56 (23%) patients, which was projected into treatment strategy. Post-treatment PET-positive patients (11/71) had shorter progression free survival (9/11 relapsed in median of 6 months) compared with PET-negative patients (56/71), 9 of whom relapsed in median of 10 months, 47 of them remain in remission (median follow up 19 months) (p<0,001) . All of remaining 4/71 patients with PET-positivity of undetermined significance (close to cut-off) are in long-term remission (median follow up 39 months). Conclusions: Our results indicate that FDG-PET is accurate and reliable method for staging of FL. Post-treatment PET positive patients are likely to relapse prior to PET negative patients. Surprisingly, presented data are very similar to those observed in studies with aggressive lymphomas.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info